Dr. Reddy's Sees Dengue Vaccine Opportunity As QDENGA Launch Nears

Dr. Reddy's Laboratories is preparing to commercialise Takeda's QDENGA in India's private vaccination market, opening up a new opportunity in the country's dengue prevention market. The vaccine is expected to be launched in India in H1 2027. For Dr. Reddy's, the partnership adds a dengue vaccine to its portfolio and gives the company an opportunity to build a private-market business around dengue prevention. The company will handle promotion and distribution, using its healthcare professional network and distribution infrastructure. Speaking with Business Today TV, M.V. Ramana, CEO - Global Generics, Dr. Reddy's Laboratories, discusses the potential size of India's dengue vaccine market, the company's revenue opportunity from QDENGA, pricing and access, and its plans for adult and paediatric vaccination.